Spero Therapeutics (SPRO) Current Leases (2019 - 2026)
Spero Therapeutics' (SPRO) quarterly Current Leases came in at $2.0 million in Q1 2026, up 9.58% YoY from $1.8 million in Q1 2025, and up 0.56% on a QoQ basis from $2.0 million in Q4 2025.
Spero Therapeutics (SPRO) Current Leases (2019 - 2026) Analysis & Trends
Spero Therapeutics (SPRO) has 8 years of Current Leases data on file, last reported at $2.0 million in Q1 2026.
- Quarterly Current Leases rose 9.58% year-over-year to $2.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.0 million (up 9.58% YoY) and the FY2025 annual result came in at $2.0 million, up 12.03% from the prior year.
- Current Leases improved to $2.0 million in Q1 2026, from $2.0 million in the prior quarter.
- In the past five years, Current Leases ranged from a high of $2.0 million in Q1 2026 to a low of $1.4 million in Q1 2022.
- A 5-year average of $1.7 million and a median of $1.7 million in 2024 frame the typical range for Current Leases.
- Annual changes were most pronounced in 2022 — Current Leases jumped 61.52% — and 2024, when it climbed 1.63%.
- Tracing SPRO's Current Leases over 5 years: stood at $1.7 million in 2022, then increased by 1.66% to $1.7 million in 2023, then gained by 1.63% to $1.7 million in 2024, then rose by 12.03% to $2.0 million in 2025, then climbed by 0.56% to $2.0 million in 2026.
- The last three Current Leases figures came in at $2.0 million (Q1 2026), $2.0 million (Q4 2025), and $1.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 21.95 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 45.93 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 6.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | - |
| 10 | Spero Therapeutics | 70.14 Mn | 19.37 Mn | - | 2.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.00 Mn |
| Mar 31, 2026 | 1.97 Mn |
| Dec 31, 2025 | 1.96 Mn |
| Sep 30, 2025 | 1.90 Mn |
| Jun 30, 2025 | 1.84 Mn |
| Mar 31, 2025 | 1.80 Mn |
| Dec 31, 2024 | 1.75 Mn |
| Sep 30, 2024 | 1.74 Mn |
| Jun 30, 2024 | 1.73 Mn |
| Mar 31, 2024 | 1.73 Mn |
| Dec 31, 2023 | 1.72 Mn |
| Sep 30, 2023 | 1.71 Mn |
| Jun 30, 2023 | 1.70 Mn |
| Mar 31, 2023 | 1.70 Mn |
| Dec 31, 2022 | 1.69 Mn |
| Sep 30, 2022 | 1.68 Mn |
| Jun 30, 2022 | 1.53 Mn |
| Mar 31, 2022 | 1.37 Mn |
| Dec 31, 2021 | 1.36 Mn |
| Sep 30, 2021 | 1.04 Mn |